Potential role of ¹²⁴I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer

References

• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• KaneCJMallinKRitcheyJCooperbergMRCarrollPRRenal cell cancer stage migration: analysis of the National Cancer Data BaseCancer20081131788318491376
   PubMed Web of Science ®Google Scholar
• CooperbergMRMallinKRitcheyJVillaltaJDCarrollPRKaneCJDecreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004J Urol200817962131213518423754
   PubMed Web of Science ®Google Scholar
• JaysonMSandersHIncreased incidence of serendipitously discovered renal cell carcinomaUrology19985122032059495698
   PubMed Web of Science ®Google Scholar
• KutikovAFossettLKRamchandaniPIncidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imagingUrology200668473774017070344
   PubMed Web of Science ®Google Scholar
• CrispenPLBoorjianSALohseCMOutcomes following partial nephrectomy by tumor sizeJ Urol200818051912191718801543
   PubMed Web of Science ®Google Scholar
• RemziMOzsoyMKlinglerHCAre small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameterJ Urol2006176389689916890647
   PubMed Web of Science ®Google Scholar
• HollingsworthJMMillerDCDaignaultSHollenbeckBKRising incidence of small renal masses: a need to reassess treatment effectJ Natl Cancer Inst200698181331133416985252
   PubMedGoogle Scholar
• WelchHGBlackWCOverdiagnosis in cancerJ Natl Cancer Inst2010102960561320413742
   PubMedGoogle Scholar
• CampbellSCNovickACBelldegrunAGuideline for management of the clinical T1 renal massJ Urol200918241271127919683266
   PubMed Web of Science ®Google Scholar
• Van PoppelHDa PozzoLAlbrechtWA prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinomaEur Urol201159454355221186077
   PubMed Web of Science ®Google Scholar
• YangGVillaltaJDMengMVWhitsonJMEvolving practice patterns for the management of small renal masses in the USABJU Int201211081156116122372984
   PubMed Web of Science ®Google Scholar
• HollenbeckBKTaubDAMillerDCDunnRLWeiJTNational utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization?Urology200667225425916442601
   PubMed Web of Science ®Google Scholar
• TanHJNortonECYeZHafezKSGoreJLMillerDCLong-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancerJAMA2012307151629163522511691
   PubMed Web of Science ®Google Scholar
• SmaldoneMCEglestonBUzzoRDoes partial nephrectomy result in a durable overall survival benefit in the elderly?J Urol20121874e449
   Web of Science ®Google Scholar
• KunkleDAEglestonBLUzzoRGExcise, ablate or observe: the small renal mass dilemma – a meta-analysis and reviewJ Urol2008179412271233 discussion 1233–123418280512
   PubMed Web of Science ®Google Scholar
• SmaldoneMCKutikovAEglestonBLSmall renal masses progressing to metastases under active surveillance: a systematic review and pooled analysisCancer20121184997100621766302
   PubMed Web of Science ®Google Scholar
• LawrentschukNDavisIDBoltonDMScottAMFunctional imaging of renal cell carcinomaNat Rev Urol20107525826620448659
   PubMed Web of Science ®Google Scholar
• LawrentschukNDavisIDBoltonDMScottAMPositron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationshipBJU Int200697591692216643471
   PubMed Web of Science ®Google Scholar
• DivgiCRPandit-TaskarNJungbluthAAPreoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trialLancet Oncol20078430431017395103
   PubMed Web of Science ®Google Scholar
• BuiMHSeligsonDHanKRCarbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapyClin Cancer Res20039280281112576453
   PubMed Web of Science ®Google Scholar
• AtkinsMReganMMcDermottDCarbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancerClin Cancer Res200511103714372115897568
   PubMed Web of Science ®Google Scholar
• LeibovichBCSheininYLohseCMCarbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinomaJ Clin Oncol200725304757476417947723
   PubMed Web of Science ®Google Scholar
• RussoPUzzoRGLowranceWIncidence of benign versus malignant renal tumors in selected studiesJ Clin Oncol201230Suppl 535722203766
   PubMed Web of Science ®Google Scholar
• GillISKavoussiLRLaneBRComparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumorsJ Urol20071781414617574056
   PubMed Web of Science ®Google Scholar
• SimhanJSmaldoneMCTsaiKJObjective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomyEur Urol201160472473021621910
   PubMed Web of Science ®Google Scholar
• HuangWCLeveyASSerioAMChronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort studyLancet Oncol20067973574016945768
   PubMed Web of Science ®Google Scholar
• FrankIBluteMLChevilleJCLohseCMWeaverALZinckeHSolid renal tumors: an analysis of pathological features related to tumor sizeJ Urol20031706 Pt 12217222014634382
   PubMed Web of Science ®Google Scholar
• ThompsonRHKurtaJMKaagMTumor size is associated with malignant potential in renal cell carcinoma casesJ Urol200918152033203619286217
   PubMed Web of Science ®Google Scholar
• RothmanJEglestonBWongYNIffrigKLebovitchSUzzoRGHistopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysisJ Urol200918112933 discussion 33–3419012902
   PubMed Web of Science ®Google Scholar
• KunkleDACrispenPLLiTTumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal massesJ Urol2007177516921696 discussion 169717437785
   PubMed Web of Science ®Google Scholar
• NguyenMMGillISEffect of renal cancer size on the prevalence of metastasis at diagnosis and mortalityJ Urol2009181310201027 discussion 102719150563
   PubMed Web of Science ®Google Scholar
• ThompsonRHHillJRBabayevYMetastatic renal cell carcinoma risk according to tumor sizeJ Urol20091821414519450840
   PubMed Web of Science ®Google Scholar
• JeldresCSunMLibermanDCan renal mass biopsy assessment of tumor grade be safely substituted for by a predictive model?J Urol200918262585258919836799
   PubMed Web of Science ®Google Scholar
• LaneBRBabineauDKattanMWA preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomyJ Urol2007178242943417561141
   PubMed Web of Science ®Google Scholar
• SchachterLRBachAMSnyderMEKattanMWRussoPThe impact of tumour location on the histological subtype of renal cortical tumoursBJU Int2006981636616831144
   PubMed Web of Science ®Google Scholar
• VenkateshRWeldKAmesCDLaparoscopic partial nephrectomy for renal masses: effect of tumor locationUrology200667611691174 discussion 117416765174
   PubMed Web of Science ®Google Scholar
• KutikovAUzzoRGThe RENAL nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depthJ Urol2009182384485319616235
   PubMed Web of Science ®Google Scholar
• KutikovASmaldoneMCEglestonBLAnatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry scoreEur Urol201160224124821458155
   PubMed Web of Science ®Google Scholar
• WangHKZhuYYaoXDExternal validation of a nomogram using RENAL nephrometry score to predict high grade renal cell carcinomaJ Urol201218751555156022425078
   PubMed Web of Science ®Google Scholar
• VolpeAFinelliAGillISRationale for percutaneous biopsy and histologic characterisation of renal tumoursEur Urol201262349150422633318
   PubMed Web of Science ®Google Scholar
• LaneBRSamplaskiMKHertsBRZhouMNovickACCampbellSCRenal mass biopsy – a renaissance?J Urol20081791202717997455
   PubMed Web of Science ®Google Scholar
• WangRWolfJSJrWoodDPJrHigginsEJHafezKSAccuracy of percutaneous core biopsy in management of small renal massesUrology2009733586590 discussion 590–59119118884
   PubMed Web of Science ®Google Scholar
• LechevallierEAndreMBarriolDFine-needle percutaneous biopsy of renal masses with helical CT guidanceRadiology2000216250651010924578
   PubMed Web of Science ®Google Scholar
• BlumenfeldAJGuruKFuchsGJKimHLPercutaneous biopsy of renal cell carcinoma underestimates nuclear gradeUrology201076361061320163843
   PubMed Web of Science ®Google Scholar
• LeveridgeMJFinelliAKachuraJROutcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsyEur Urol201160357858421704449
   PubMed Web of Science ®Google Scholar
• PalSKKortylewskiMYuHFiglinRABreaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkersMol Cancer Ther20109123115312521078774
   PubMed Web of Science ®Google Scholar
• LjungbergBCowanNCHanburyDCEAU guidelines on renal cell carcinoma: the 2010 updateEur Urol201058339840620633979
   PubMed Web of Science ®Google Scholar
• MotzerRJAgarwalNBeardCNCCN clinical practice guidelines in oncology: kidney cancerJ Natl Compr Canc Netw20097661863019555584
   PubMed Web of Science ®Google Scholar
• VikramRCaslinoDDRemerEMACR appropriateness criteria: renal cell carcinoma staging Available from: http://www.acr.org/~/media/ACR/Documents/AppCriteria/Diagnostic/RenalCellCarcinomaStaging.pdf.1995 Last reviewed 2011Accessed October 23, 2012
   Google Scholar
• GraserABeckerCRStaehlerMSingle-phase dual-energy CT allows for characterization of renal masses as benign or malignantInvest Radiol201045739940520498609
   PubMed Web of Science ®Google Scholar
• GiletAGKangSKKimDChandaranaHAdvanced renal mass imaging: diffusion and perfusion MRICurr Urol Rep2012131939822081252
   PubMed Web of Science ®Google Scholar
• TaouliBThakurRKMannelliLRenal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imagingRadiology2009251239840719276322
   PubMed Web of Science ®Google Scholar
• SunMRNgoLGenegaEMRenal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes – correlation with pathologic findingsRadiology2009250379380219244046
   PubMed Web of Science ®Google Scholar
• SmaldoneMCChenDYUzzoRGYuMMolecular imaging of the small renal massUrol Oncol201129658959222078404
   PubMed Web of Science ®Google Scholar
• WeberWAGrosuALCzerninJTechnology Insight: advances in molecular imaging and an appraisal of PET/CT scanningNat Clin Pract Oncol20085316017018253106
   PubMedGoogle Scholar
• HicksRJWareRELauEWPET/CT: will it change the way that we use CT in cancer imaging?Cancer Imaging20066S52S6217114079
   PubMedGoogle Scholar
• AideNCappeleOBottetPEfficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CTEur J Nucl Med Mol Imaging20033091236124512845486
   PubMed Web of Science ®Google Scholar
• MotzerRJBukowskiRMTargeted therapy for metastatic renal cell carcinomaJ Clin Oncol200624355601560817158546
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• WahlRLJaceneHKasamonYLodgeMAFrom RECIST to PERCIST: evolving considerations for PET response criteria in solid tumorsJ Nucl Med200950Suppl 1122S150S19403881
   PubMed Web of Science ®Google Scholar
• VercellinoLBousquetGBailletG18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary studyCancer Biother Radiopharm200924113714419243256
   PubMed Web of Science ®Google Scholar
• UenoDYaoMTateishiUEarly assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease courseBMC Cancer201212116222551397
   PubMed Web of Science ®Google Scholar
• KayaniIAvrilNBomanjiJSequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancerClin Cancer Res201117186021602821742806
   PubMed Web of Science ®Google Scholar
• HarrisonMRGeorgeDJBetter late than early: FDG-PET imaging in metastatic renal cell carcinomaClin Cancer Res201117185841584321926167
   PubMed Web of Science ®Google Scholar
• OyamaNOkazawaHKusukawaN11C-Acetate PET imaging for renal cell carcinomaEur J Nucl Med Mol Imaging200936342242719018529
   PubMed Web of Science ®Google Scholar
• OzülkerTOzülkerFOzbekEOzpaçaciTA prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal massesNucl Med Commun201132426527221301376
   PubMed Web of Science ®Google Scholar
• LawrentschukNPoonAMScottAMFluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumorsClin Nucl Med2006311278878917117073
   PubMed Web of Science ®Google Scholar
• LawrentschukNPoonAMFooSSAssessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomographyBJU Int200596454054616104907
   PubMed Web of Science ®Google Scholar
• van DongenGAPootAJVugtsDJPET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PETTumour Biol201233360761522270450
   PubMedGoogle Scholar
• TolmachevVStone-ElanderSRadiolabelled proteins for positron emission tomography: pros and cons of labelling methodsBiochim Biophys Acta20101800548751020153401
   PubMed Web of Science ®Google Scholar
• OlafsenTWuAMAntibody vectors for imagingSemin Nucl Med201040316718120350626
   PubMed Web of Science ®Google Scholar
• OosterwijkERuiterDJHoedemaekerPJMonoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidneyInt J Cancer19863844894942428759
   PubMed Web of Science ®Google Scholar
• OosterwijkEDe WeijertMVan BokhovenABrakenhoffRHPeelenWPDebruyneFMJMolecular characterization of the renal cell carcinoma-associated antigen G250Proc Amer Assoc Cancer Res199637461
   Google Scholar
• van DijkJUemuraHBeniersAJTherapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenograftsInt J Cancer19945622622688314310
   PubMed Web of Science ®Google Scholar
• UemuraHBeniersAJOkajimaEDebruyneFMOosterwijkEVaccination with anti-idiotype antibodies mimicking a renal cell carcinoma-associated antigen induces tumor immunityInt J Cancer19945845555618056452
   PubMed Web of Science ®Google Scholar
• UemuraHOkajimaEDebruyneFMOosterwijkEInternal image anti-idiotype antibodies related to renal-cell carcinoma-associated antigen G250Int J Cancer19945646096147509324
   PubMed Web of Science ®Google Scholar
• DivgiCRBanderNHScottAMPhase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinomaClin Cancer Res1998411272927399829736
   PubMed Web of Science ®Google Scholar
• SteffensMGBoermanOCOosterwijk-WakkaJCTargeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250J Clin Oncol1997154152915379193349
   PubMed Web of Science ®Google Scholar
• LamJSPantuckAJBelldegrunASFiglinRAG250: a carbonic anhydrase IX monoclonal antibodyCurr Oncol Rep20057210911515717944
   PubMedGoogle Scholar
• StillebroerABMuldersPFBoermanOCOyenWJOosterwijkECarbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapyEur Urol2010581758320359812
   PubMed Web of Science ®Google Scholar
• SmaldoneMCMaranchieJKClinical implications of hypoxia inducible factor in renal cell carcinomaUrol Oncol200927323824519414111
   PubMed Web of Science ®Google Scholar
• IvanovSLiaoSYIvanovaAExpression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancerAm J Pathol2001158390591911238039
   PubMed Web of Science ®Google Scholar
• PotterCHarrisALHypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy targetCell Cycle20043216416714712082
   PubMed Web of Science ®Google Scholar
• TostainJLiGGentil-PerretAGiganteMCarbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatmentEur J Cancer201046183141314820709527
   PubMed Web of Science ®Google Scholar
• SandlundJOosterwijkEGrankvistKOosterwijk-WakkaJLjungbergBRasmusonTPrognostic impact of carbonic anhydrase IX expression in human renal cell carcinomaBJU Int2007100355656017608827
   PubMed Web of Science ®Google Scholar
• PatardJJFergelotPKarakiewiczPILow CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinomaInt J Cancer2008123239540018464292
   PubMed Web of Science ®Google Scholar
• de MartinoMKlatteTSeligsonDBCA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosisJ Urol2009182272873419539328
   PubMed Web of Science ®Google Scholar
• KimHLSeligsonDLiuXUsing tumor markers to predict the survival of patients with metastatic renal cell carcinomaJ Urol200517351496150115821467
   PubMed Web of Science ®Google Scholar
• KimHLSeligsonDLiuXUsing protein expressions to predict survival in clear cell renal carcinomaClin Cancer Res200410165464547115328185
   PubMed Web of Science ®Google Scholar
• OosterwijkEBanderNHDivgiCRAntibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250J Clin Oncol19931147387508478666
   PubMed Web of Science ®Google Scholar
• BrouwersAHDorrULangO131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative studyNucl Med Commun200223322923611891480
   PubMed Web of Science ®Google Scholar
• BrouwersAHBuijsWCMuldersPFRadioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic responseClin Cancer Res20051119 Pt 27178s7186s16203819
   PubMed Web of Science ®Google Scholar
• BrouwersAHMuldersPFde MulderPHLack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinomaJ Clin Oncol200523276540654816170161
   PubMed Web of Science ®Google Scholar
• BrouwersAHBuijsWCOosterwijkETargeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparisonClin Cancer Res2003910 Pt 23953S3960S14506194
   PubMed Web of Science ®Google Scholar
• BleumerIKnuthAOosterwijkEA phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patientsBr J Cancer200490598599014997194
   PubMed Web of Science ®Google Scholar
• DavisIDWisemanGALeeFTA phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinomaCancer Immun200771317705349
   PubMedGoogle Scholar
• BleumerIOosterwijkEOosterwijk-WakkaJCA clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin- 2 pulsing scheme for advanced renal cell carcinomaJ Urol20061751576216406869
   PubMed Web of Science ®Google Scholar
• SteffensMGBoermanOCde MulderPHPhase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250Clin Cancer Res19995Suppl 103268s3274s10541374
   PubMed Web of Science ®Google Scholar
• DivgiCRO’DonoghueJAWeltSPhase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancerJ Nucl Med20044581412142115299069
   PubMed Web of Science ®Google Scholar
• SiebelsMRohrmannKObernederRA clinical phase I/II trial with the monoclonal antibody cG250 (Rencarex) and interferon- alpha-2a in metastatic renal cell carcinoma patientsWorld J Urol201129112112620512580
   PubMed Web of Science ®Google Scholar
• BauerSOosterwijk-WakkaJCAdrianNTargeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNgInt J Cancer2009125111512319384924
   PubMed Web of Science ®Google Scholar
• BleumerITiemessenDMOosterwijk-WakkaJCPreliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cellsJ Immunother200730111612217198090
   PubMed Web of Science ®Google Scholar
• UemuraHFujimotoKTanakaMA phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinomaClin Cancer Res20061261768177516551861
   PubMed Web of Science ®Google Scholar
• PelosiEMessaCSironiSValue of integrated PET/CT for lesion localisation in cancer patients: a comparative studyEur J Nucl Med Mol Imaging200431793293914991245
   PubMed Web of Science ®Google Scholar
• BrouwersAVerelIVan EerdJPET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude ratsCancer Biother Radiopharm200419215516315186595
   PubMed Web of Science ®Google Scholar
• VerelIVisserGWBoermanOCLong-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PETCancer Biother Radiopharm200318465566114503961
   PubMed Web of Science ®Google Scholar
• UzzoRGRussoPChenDThe multicenter phase III Redect trial: a comparative study of 124 I-girentuximab-PET/CT versus diagnostic CT for the pre-operative diagnosis of clear cell renal cell carcinoma (ccRCC) [late-breaking abstract]AUA Annual MeetingMay 29–June 3 2010San Francisco, CA, USA
   Google Scholar
• RussoPJangTLPettusJASurvival rates after resection for localized kidney cancer: 1989 to 2004Cancer20081131849618470927
   PubMed Web of Science ®Google Scholar
• BrouwersAHMuldersPFOyenWJCarbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapyJ Clin Oncol2008262238083309 author reply 11–1218669472
   PubMed Web of Science ®Google Scholar
• BeckSDPatelMISnyderMEEffect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinomaAnn Surg Oncol2004111717714699037
   PubMed Web of Science ®Google Scholar